Novartis Investigational STAMP Inhibitor Asciminib (ABL001) Shows Superior MMR Rate to Bosulif®* in Chronic Myeloid Leukemia Trial
EAST HANOVER, N.J., Dec. 8, 2020 /PRNewswire/ — Detailed results from the Phase III ASCEMBL study demonstrate that, at 24 weeks, asciminib (ABL001)
Read more